Evercore ISI Upgrades Agilent Technologies (NYSE:A) to “Outperform”

Agilent Technologies (NYSE:A) was upgraded by research analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a research note issued on Monday,Finviz reports. The firm currently has a $160.00 target price on the medical research company’s stock. Evercore ISI’s target price suggests a potential upside of 16.09% from the stock’s current price.

A has been the topic of several other research reports. TD Cowen increased their price target on Agilent Technologies from $150.00 to $162.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Agilent Technologies in a research note on Monday, December 29th. Morgan Stanley initiated coverage on shares of Agilent Technologies in a research note on Tuesday, December 2nd. They set an “overweight” rating for the company. Citigroup increased their price objective on shares of Agilent Technologies from $165.00 to $185.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Finally, Rothschild & Co Redburn started coverage on Agilent Technologies in a research report on Wednesday, October 8th. They set a “buy” rating and a $165.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.31.

Agilent Technologies Stock Up 1.3%

Shares of NYSE:A opened at $137.82 on Monday. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 0.45. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $160.27. The company has a 50-day moving average price of $144.41 and a 200 day moving average price of $131.60. The company has a market cap of $39.07 billion, a price-to-earnings ratio of 30.16, a PEG ratio of 4.00 and a beta of 1.29.

Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.01. The company had revenue of $1.86 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.46 earnings per share. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS and its FY 2026 guidance at 5.860-6.000 EPS. As a group, equities research analysts predict that Agilent Technologies will post 5.58 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Padraig Mcdonnell sold 12,490 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total transaction of $1,873,500.00. Following the transaction, the chief executive officer directly owned 33,448 shares of the company’s stock, valued at approximately $5,017,200. This trade represents a 27.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Rodney Gonsalves sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $154.99, for a total value of $464,970.00. Following the completion of the sale, the vice president owned 31,846 shares of the company’s stock, valued at $4,935,811.54. The trade was a 8.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 16,401 shares of company stock worth $2,468,962.

Hedge Funds Weigh In On Agilent Technologies

Institutional investors have recently made changes to their positions in the company. Resona Asset Management Co. Ltd. increased its position in Agilent Technologies by 6.2% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock valued at $11,631,000 after purchasing an additional 5,767 shares during the period. TrueMark Investments LLC bought a new position in shares of Agilent Technologies during the second quarter valued at approximately $1,999,000. Nuance Investments LLC increased its holdings in Agilent Technologies by 13.5% during the second quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock valued at $9,523,000 after buying an additional 9,628 shares during the period. Fenimore Asset Management Inc raised its stake in Agilent Technologies by 2.7% in the second quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock worth $21,346,000 after buying an additional 4,823 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Agilent Technologies by 472.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 221,993 shares of the medical research company’s stock worth $26,197,000 after buying an additional 183,220 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.